IGF2BP3 and chronic kidney disease: We first assessed the expression of IGF2BP3 in various well-established animal models of CKD induced by unilateral ureteral obstruction (UUO), ischemia/reperfusion injury (IRI), adriamycin (ADR), and angiotensin II (Ang II), respectively.